<DOC>
	<DOCNO>NCT00688766</DOCNO>
	<brief_summary>IPI-504-06 Phase 3 , randomize , double-blind , placebo-controlled , multi-center study evaluate efficacy safety IPI-504 compare placebo patient metastatic and/or unresectable GIST follow failure least imatinib sunitinib . Approximately 195 patient randomize use 2:1 ratio receive either IPI-504 ( N=130 ) placebo ( N=65 ) . Upon unblinding , patient receive either IPI-504 placebo may receive IPI-504 open-label portion study define inclusion criterion meet . Early frequent imaging timepoints ( Weeks 2 , 5 , 8 , 14 every 6 week thereafter ) incorporate study capture progression event limit patient exposure ineffective agent .</brief_summary>
	<brief_title>Study Evaluating IPI-504 Patients With Gastrointestinal Stromal Tumors ( GIST ) Following Failure Least Imatinib Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>At least 18 year age time study randomization . Histologically confirm metastatic and/or unresectable GIST . Measurable disease CT MRI define RECIST . Documented radiographic progression intolerance imatinib sunitinib . Clinical failure recent prior therapy GIST . Note : There limit number prior therapy patient may receive . Eastern Cooperative Oncology Group ( ECOG ) performance status : 0 1 . Hemoglobin ≥ 8.0 g/dL ( 80 g/L ) . Absolute Neutrophil Count ≥ 1500/µL ( 1.5 x 109/L ) . Platelets ≥ 100,000 /µL ( 100 x 109/L ) . ALT AST ≤ 2.5 x upper limit normal ( ULN ) , ≤ 5.0 x ULN consider secondary liver metastasis . Alkaline phosphatase ≤ 2.5 x ULN , ≤ 5.0 x ULN consider secondary liver metastasis . Serum bilirubin ≤ 1.5 x ULN . PT PTT ≤ 1.5 x ULN unless patient receive warfarin . If patient receive warfarin , INR must within therapeutic range . Serum creatinine ≤ 1.5 x ULN . Previous administration know heat shock protein 90 ( Hsp90 ) inhibitor . Surgery , radiotherapy , lesion ablative procedure area measurable disease . Initiation discontinuation concurrent medication potent CYP3A inhibitor le 2 week prior administration IPI504 placebo . History follow within last 6 month : cardiac disease acute coronary syndrome unstable angina , symptomatic congestive heart failure , uncontrolled hypertension , cirrhotic liver disease , cerebrovascular accident , significant comorbid condition disease , judgment investigator , would place patient undue risk interfere study . Grade 3 4 hemorrhagic event within last 6 month . Known human immunodeficiency virus positivity . Sinus bradycardia ( rest heart rate &lt; 50 bpm ) secondary intrinsic conduction system disease . QTcF ≥ 470 millisecond , previous history clinically significant QTc prolongation take medication . History prior malignancy within past 3 year nonmelanomatous skin cancer control , prostate cancer treat recur , nonmuscleinvasive bladder cancer , carcinoma situ cervix . Active recent history ( within 3 month ) keratitis keratoconjunctivitis confirm ophthalmology optometry exam . Presence Left Bundle Branch Block , Right Bundle Branch Block plus leave anterior hemiblock , bifascicular block , 3rd degree heart block . This include patient history event adequate control pacemaker . Known CNS metastasis . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>GIST</keyword>
	<keyword>Metastatic and/or Unresectable Gastrointestinal Stromal</keyword>
</DOC>